This report presents a case of a lung adenocarcinoma patient with an EGFR L858R mutation who failed a third-generation EGFR-TKI rechallenge after recovering from initial osimertinib-induced ILD, along with a literature review. The gene discussed is EGFR; the disease is interstitial lung disease.